Filing Details
- Accession Number:
- 0001140361-24-042559
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-02 16:06:04
- Reporting Period:
- 2024-09-30
- Accepted Time:
- 2024-10-02 16:06:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 887359 | Vericel Corp | VCEL | Biological Products, (No Disgnostic Substances) (2836) | 943096597 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1916145 | Jonathan Siegal | 64 Sidney Street Cambridge MA 02139 | Principal Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-30 | 937 | $0.00 | 2,061 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-30 | 369 | $42.25 | 1,692 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2024-10-01 | 568 | $41.90 | 1,124 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Acquisiton | 2024-09-30 | 937 | $0.00 | 937 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 938 | No | 4 | M | Direct |
Footnotes
- The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on September 30, 2021. The remaining RSUs will vest on September 30, 2025.
- These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024.
- Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
- No expiration date for this type of award.
- The Fair Market Value of the vested derivative securities is $42.25 per share.
Billionaire Hedge Funds
